ECE2014 Poster Presentations Diabetes therapy (40 abstracts)
Liraglutide effects on glycaemic control, body weight, blood pressure and lipid profile in obese patients with type 2 diabetes: real-life clinical practice
Jose Carlos Fernandez-Garcia 1 , Isabel Mancha-Doblas 1 , Carmen Maria Cortes-Salazar 2 , Maria Jose Picón-César 1 , Ana Maria Gomez-Perez 1 , Mar Roca 1 & Francisco Tinahones 1
1Endocrinology Department, Virgen de la Victoria University Hospital, Malaga, Spain; 2Primary Care Center El Palo, Malaga, Spain.
Objective: To evaluate the efficacy of liraglutide, a new glucagon-like peptide 1 analogue, on glycaemic control, body weight, blood pressure and lipid profile in obese patients with type 2 diabetes mellitus (T2DM).
Material and methods: Patients attending a tertiary Endocrinology Unit who were prescribed liraglutide (January 2013–December 2013) and assessed both at baseline and first post-initiation visit were included in the analysis. The primary endpoint was change in HbA1c from baseline. Body weight, blood pressure, lipid profile, adverse effects and frequency of hypoglycaemic events were also assessed.
Results: 48 obese (mean weight 106.9±19 kg and mean BMI 39.8±5.1 kg/m2) type 2 diabetic patients (mean age 53.6±10.4 years and men 43.8%), started treatment with liraglutide in the study period. Mean baseline HbA1c was 8.6±1.2%, mean baseline systolic blood pressure (SBP) levels were 150.3±19.3 mmHg and diastolic blood pressure (DBP) were 86.9±10.6 mmHg. Baseline concentrations of total cholesterol, HDL-cholesterol, LDL-cholesterol and triglycerides were 190±45.3, 41.6±11.5, 112.2±36.6 and 266.1±194.6 mg/dl respectively. Average time to first visit after liraglutide initiation was 18.6 weeks. Mean change in HbA1c from initiation to first visit was −1.3%, while mean body weight change was −3.4 kg, and change in SBP was −10.5 mmHg (P for all <0.005). No changes in lipid profile or DBP were found. Mild transient gastrointestinal side effects were experienced by 18.4% of patients. None patient discontinued liraglutide treatment or reported hypoglycaemia.
Conclusion: In real-life clinical practice, addition of liraglutide in patients with T2DM inadequately controlled improves glycaemic control, decreases body weight, and lowers blood pressure.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more